Background Gabapentinoid (pregabalin and gabapentin) abuse is increasingly being
reported. Objective To assess the extent of gabapentinoid abuse, characteristics of typical …

Abstract Background and Aims Since its market release, gabapentin has been presumed to
have no abuse potential and subsequently has been prescribed widely off‐label, despite …

In the last ten years, gabapentin and pregabalin have been becoming dispensed broadly
and sold on black markets, thereby, exposing millions to potential side-effects. Meanwhile …

This review summarizes current evidence on the abuse and misuse of the gabapentinoids
pregabalin and gabapentin. Pharmacovigilance studies, register-based studies, surveys …

This article will review the epidemiology and pharmacology of gabapentinoids (gabapentin
and pregabalin) relevant to their emerging misuse potential and provide guidance for …

Background Although there have been increasing reports of intentional gabapentin misuse,
epidemiological evidence for the phenomenon is limited. The purpose of this study was to …

Background Despite international calls to make gabapentin a controlled substance, studies
of gabapentin use/abuse patterns are limited to small/high-risk samples and adverse event …

Gabapentin is approved to treat postherpetic neuralgia and epilepsy with partial-onset
seizures. The large majority of gabapentin prescribing is off label. Gabapentin may be …

Background: Gabapentin is increasingly recognised for its potential for abuse, raising
concerns within healthcare communities. Community pharmacists are on the front lines in …

Background With increasing efforts to scrutinize and reduce opioid prescribing, limited data
exist on the recent trend in receipt of prescription pain medications before diagnosis of …